Cipla receives USFDA nod for Lopinavir, Ritonavir oral pellets

04 Jun 2015 Evaluate

Cipla, a global pharmaceutical company, has received United States Food and Drug Administration (USFDA) approval for an innovative formulation - Lopinavir/ ritonavir (LPV/r) 40mg/ 10 mg oral pellets - for paediatric specific treatment for infants.

Cipla has long recognized the lack of access to life saving child-friendly formulations for the treatment of HIV, which prompted it to develop an innovative formulation of LPV/r oral pellets. The pellets are to be sprinkled on sweetened porridge for infants and administered to them. The pellets are produced by melt-extrusion technology and are enclosed in capsules.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Its portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.



Cipla Share Price

1399.35 -20.70 (-1.46%)
17-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1530.00
Dr. Reddys Lab 5802.00
Cipla 1399.35
Zydus Lifesciences 1051.90
Lupin 1653.75
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.